V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016004 | 160018055 | 0 | 56.3 | Curative (C) | 2016-04-14 | 2016-09-22 | Niraparib | N | Y | NIRAPARIB | 100927957 |
| 160016007 | 160018056 | 1.67 | 78.5 | null | 2016-01-08 | 2016-06-08 | PEMBROLIZUMAB | 02 | null | TRIAL | 100885300 |
| 160016036 | 160018058 | 1.66 | 63.9 | Curative (C) | 2018-04-21 | 2022-01-12 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | LANREOTIDE | 100744831 |
| 160016038 | 160018059 | 1.76 | 53.8 | Palliative (P) | 2019-01-11 | 2019-01-17 | CONFIRM TRIAL | null | N | IRINOTECAN + VINCRISTINE | 101849043 |
| 160016054 | 160018061 | 1.58 | 15.8 | Curative (C) | 2019-09-27 | 2019-10-01 | Ifosfamide | N | N | NEMO TRIAL | 101490712 |
| 160016059 | 160018062 | null | 85.75 | null | 2016-11-20 | 2017-03-03 | PEMBROLIZUMAB | 99 | null | GEMCITABINE | 101423964 |
| 160016071 | 160018063 | 1.25 | 85.9 | null | null | 2019-12-01 | null | null | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101610285 |
| 160016102 | 160018064 | 1.54 | 56.8 | Palliative (P) | 2019-08-15 | 2019-08-15 | Ifosfamide PVI 1g/m2 14day | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100224260 |
| 160016118 | 160018065 | 1.79 | 95 | Curative (C) | 2020-05-14 | 2020-05-19 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | RUCAPARIB | 101008628 |
| 160016120 | 160018066 | 1.78 | 18.5 | Neo-adjuvant (N) | 2019-01-13 | 2019-01-15 | EW EuroEwing 2012 Arm B VC | 02 | N | EW EUROEWING 2012 ARM B IE | 101614220 |
| 160016122 | 160018067 | 1.6 | 104 | null | 2018-08-03 | 2019-07-07 | null | N | null | NOT MATCHED | 100365512 |
| 160016126 | 160018068 | 1.58 | 49.6 | Palliative (P) | 2019-05-16 | 2020-02-20 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100019798 |
| 160016128 | 160018069 | 1.77 | 77.47 | null | 2020-06-09 | 2020-06-23 | Ifosfamide | 02 | null | PAZOPANIB | 101536348 |
| 160016143 | 160018070 | 1.63 | 0 | null | null | 2018-06-11 | NB HRNBL-1 BUMEL MAT | 02 | null | LENALIDOMIDE | 101844682 |
| 160016154 | 160018071 | null | 36.5 | null | 2019-05-02 | 2019-07-07 | ETOP 13-18 BEAT-meso Trial | null | null | NB HRNBL-1 COJEC IND COURSE C | 100806339 |
| 160016155 | 160018072 | 1.9 | 72.5 | Palliative (P) | 2020-10-08 | 2020-10-08 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100008589 |
| 160016166 | 160018073 | 0 | 97.8 | Curative (C) | 2018-10-21 | 2019-02-09 | Gemcitabine day 1&8 | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100421690 |
| 160016172 | 160018075 | 1.83 | 87.2 | Curative (C) | 2016-10-01 | 2016-10-04 | NEMO TRIAL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101857592 |
| 160016178 | 160018076 | 1.69 | 14.7 | Neo-adjuvant (N) | 2020-07-21 | 2020-08-05 | EW EuroEwing 2012 Arm B IE | 02 | N | IFOSFAMIDE | 100892173 |
| 160016183 | 160018077 | 1.82 | 85.75 | Curative (C) | 2018-01-14 | 2018-01-16 | NB HRNBL-1 COJEC Ind COURSE C | null | N | NB LOW/INTERMED RISK GUIDELINES CADO | 100705666 |
| 160016208 | 160018078 | 1.65 | 148 | Curative (C) | 2021-04-14 | 2021-04-14 | Doxorubicin + Ifosfamide | 02 | N | PEMBROLIZUMAB | 101453452 |
| 160016209 | 160018079 | 1.7 | 93.9 | Palliative (P) | 2021-06-17 | 2021-07-17 | Ifosfamide + Liposomal Doxorubicin | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100261378 |
| 160016212 | 160018080 | 1.93 | 11.8 | null | 2020-10-24 | 2020-11-28 | BLEOMYCIN | 02 | null | STS NON-RHABDO EPSSG 2005 IVA | 100469851 |
| 160016214 | 160018081 | 0 | 75.2 | Curative (C) | 2018-06-22 | 2018-09-04 | NB HRNBL-1 TVD | 02 | N | IPILIMUMAB + NIVOLUMAB | 100377752 |
| 160016215 | 160018082 | 1.63 | 110 | null | 2018-06-13 | 2018-07-04 | GemCarbo Days 1+8 | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101711099 |
| 160016216 | 160018083 | null | 82.3 | Palliative (P) | null | 2020-01-21 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | POMALIDOMIDE | 100889867 |
| 160016227 | 160018084 | 1.86 | 74 | Palliative (P) | 2018-11-25 | 2018-11-26 | STS Rhabdomyosarcoma RMS 2005 IVA | 99 | N | TRIAL | 100301185 |
| 160016234 | 160018085 | 1.6 | 62.3 | null | 2017-11-06 | 2018-11-08 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | null | ENZALUTAMIDE | 101787831 |
| 160016264 | 160018086 | 1.72 | 17.8 | null | 2016-12-11 | 2016-12-13 | Pemetrexed | 02 | null | IPILIMUMAB + NIVOLUMAB | 100463884 |
| 160016268 | 160018087 | null | 93.5 | null | 2020-10-19 | 2020-10-27 | EW EuroEwing 2012 Arm B VDC | 02 | null | CONFIRM TRIAL | 101200519 |
| 160016279 | 160018089 | 1.78 | 106 | null | 2021-12-16 | 2021-12-22 | IPM | 99 | null | NIRAPARIB | 100874490 |
| 160016287 | 160018090 | null | 69.35 | null | 2018-04-01 | 2018-09-10 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101210219 |
| 160016291 | 160018091 | 0 | 91.2 | Palliative (P) | 2018-06-19 | 2018-07-04 | Eribulin | 01 | Y | CYCLOPHOSPHAMIDE HIGH DOSE | 100344862 |
| 160016301 | 160018092 | 0 | 92.7 | Neo-adjuvant (N) | 2017-02-13 | 2017-02-15 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | CARBOPLATIN + VINORELBINE | 100811274 |
| 160016304 | 160018093 | 0 | 80.6 | Palliative (P) | 2018-03-28 | 2018-05-09 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | OLAPARIB | 100017071 |
| 160016308 | 160018094 | 1.69 | null | 03 | 2019-05-27 | 2019-06-09 | Niraparib | 02 | N | CARBOPLATIN + ETOPOSIDE | 101681747 |
| 160016309 | 160018095 | 0 | 31 | Neo-adjuvant (N) | 2014-10-25 | 2019-02-18 | STS Rhabdo VIT0910 Vinc Irino Temoz | 01 | N | EW EUROEWING 2012 ARM A VAC | 100318550 |
| 160016314 | 160018096 | null | null | Curative (C) | 2017-10-02 | 2018-05-23 | Etoposide oral | 02 | null | NOT MATCHED | 100726127 |
| 160016316 | 160018097 | 1.51 | 75.8 | null | 2017-07-03 | 2017-07-03 | ETOP 13-18 BEAT-meso Trial | 02 | N | NIRAPARIB | 100605956 |
| 160016320 | 160018098 | 1.62 | 54 | Neo-adjuvant (N) | 2019-06-12 | 2019-06-12 | Cyclophosphamide oral | 02 | N | DACARBAZINE + GEMCITABINE | 101769475 |
| 160016323 | 160018099 | 1.6 | 104 | Palliative (P) | 2018-01-28 | 2019-10-01 | Olaparib | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101402071 |
| 160016342 | 160018100 | 1 | 74.7 | Palliative (P) | 2020-03-14 | 2020-03-28 | Olaratumab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100428007 |
| 160016345 | 160018101 | 1 | 10.9 | Palliative (P) | 2019-09-26 | 2020-04-27 | Ifosfamide 3g/m2 5 day | 02 | N | ETOPOSIDE | 100784492 |
| 160016348 | 160018102 | 1.64 | 13 | Palliative (P) | 2018-01-23 | 2018-03-07 | LUTETIUM-177 | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100954658 |
| 160016356 | 160018103 | 1.63 | 83 | Neo-adjuvant (N) | 2018-05-09 | 2018-05-16 | null | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100530545 |
| 160016361 | 160018104 | 0 | null | Curative (C) | 2021-11-03 | 2021-11-03 | EW EuroEwing 2012 Arm B IE | 02 | null | IMATINIB | 101091128 |
| 160016362 | 160018105 | 1.78 | 48.9 | Palliative (P) | 2018-10-15 | 2018-11-06 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | LORLATINIB | 101279426 |
| 160016366 | 160018106 | 1.86 | 40.7 | Adjuvant (A) | 2018-10-11 | 2019-01-17 | EpSSG NRSTS 2005 | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101311932 |
| 160016368 | 160018107 | 1.7 | null | Palliative (P) | 2018-12-28 | 2018-12-29 | Ifosfamide | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101578769 |
| 160016371 | 160018108 | 1.62 | 10.5 | null | 2017-10-04 | 2018-05-09 | Dacarbazine | 02 | null | CYCLOPHOSPHAMIDE + VINCRISTINE | 101092422 |